Exenatide ( DrugBank: Exenatide )


6 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病10
17多系統萎縮症2
72下垂体性ADH分泌異常症1
78下垂体前葉機能低下症2
193プラダー・ウィリ症候群3
233ウォルフラム症候群1

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04269642
(ClinicalTrials.gov)
March 19, 202013/1/2020SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's DiseasePhase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's DiseaseEarly Parkinson's DiseaseDrug: PT320 2.0mg Placebo;Drug: PT320 2.0 mg;Drug: PT320 2.5 mgPeptron, Inc.NULLActive, not recruiting40 Years75 YearsAll99Phase 2Korea, Republic of
2NCT04305002
(ClinicalTrials.gov)
January 21, 202020/2/2020Exenatide Treatment in Parkinson's DiseaseEffect of Exenatide on Disease Progression in Early Parkinson's DiseaseParkinson DiseaseDrug: Exenatide;Drug: PlaceboCenter for Neurology, StockholmKarolinska InstitutetActive, not recruiting25 Years80 YearsAll60Phase 2Sweden
3NCT04232969
(ClinicalTrials.gov)
January 20, 202010/1/2020Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseA Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseParkinson's DiseaseDrug: Exenatide extended release 2mg (Bydureon)University College, LondonNULLActive, not recruiting25 Years80 YearsAll194Phase 3United Kingdom
4EUCTR2019-000732-26-SE
(EUCTR)
23/10/201907/05/2019Exenatide Treatment in Parkinson's DiseaseEffect of Exenatide on disease progression in early Parkinson's disease. Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Bydureon 2 mg powder and solvent for prolonged-release suspension
Product Name: BYDUREON
INN or Proposed INN: EXENATIDE
Stockholm Health Care ServicesNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2Sweden
5EUCTR2018-003028-35-GB
(EUCTR)
04/09/201915/11/2019A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease. - Phase 3 Trial of exenatide for Parkinson’s disease Parkinson's disease
MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Bydureon
Product Name: Bydureon
INN or Proposed INN: Exenatide
University College London Comprehensive Clinical Trial UnitNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
200 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited Kingdom
6NCT03456687
(ClinicalTrials.gov)
June 5, 20181/3/2018Effects of Exenatide on Motor Function and the BrainEffects of Exenatide on Motor Function and the BrainParkinson's DiseaseDrug: ExenatideUniversity of FloridaNational Institute of Neurological Disorders and Stroke (NINDS)Completed40 Years77 YearsAll5Phase 1United States
7NCT01971242
(ClinicalTrials.gov)
June 201423/10/2013Trial of Exenatide for Parkinson's DiseaseA Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's DiseaseParkinson's DiseaseDrug: Exenatide;Other: PlaceboUniversity College, LondonNULLCompleted25 Years75 YearsBoth60Phase 2United Kingdom
8EUCTR2013-003363-64-GB
(EUCTR)
03/04/201411/03/2014Trial of Exenatide for Parkinson's diseaseA randomised, double blind, placebo controlled, single centre, 60 week trial of Exenatide once weekly for the treatment of moderate severity Parkinson’s disease. - Exenatide-PD Parkinson's Disease
MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Bydureon
Product Name: Exenatide
INN or Proposed INN: exenatide
University College LondonNULLNot RecruitingFemale: yes
Male: yes
60Phase 2United Kingdom
9NCT01174810
(ClinicalTrials.gov)
July 20102/8/2010Exendin-4 as a Treatment for Parkinson's Disease - Pilot StudyAn Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exendin-4 (Exenatide) in the Treatment of Patients With Moderate Severity Parkinson's Disease.Parkinson's DiseaseDrug: ExenatideUniversity College, LondonNULLActive, not recruiting45 Years70 YearsBoth40Phase 2United Kingdom
10EUCTR2009-018137-37-GB
(EUCTR)
14/04/201018/03/2010An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trialAn open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trial Parkinson's disease
MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
Trade Name: Byetta 5 micrograms
Product Name: Exenatide 5 micrograms
Trade Name: Exenatide 10 micrograms
Product Name: Exenatide 10 micrograms
University College LondonNULLNot Recruiting Female: yes
Male: yes
40 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom

17. 多系統萎縮症


臨床試験数 : 119 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04431713
(ClinicalTrials.gov)
September 16, 202029/5/2020Exenatide Once-weekly as a Treatment for Multiple System AtrophyAn Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exenatide Once-weekly in the Treatment of Patients With Multiple System AtrophyMultiple System AtrophyDrug: Exenatide Pen Injector [Bydureon]University College, LondonNULLRecruiting30 Years80 YearsAll50Phase 2United Kingdom
2EUCTR2020-000122-26-GB
(EUCTR)
11/05/202006/04/2020Exenatide once-weekly as a treatment for Multiple System Atrophy.A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and efficacy of Exenatide once-weekly in the treatment of patients with Multiple System Atrophy - Exenatide once-weekly as a treatment for Multiple System Atrophy. Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders
Trade Name: Bydureon
Product Name: Bydureon
INN or Proposed INN: Exenatide
University College London (UCL)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2United Kingdom

72. 下垂体性ADH分泌異常症


臨床試験数 : 41 薬物数 : 27 - (DrugBank : 8) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 10
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04897802
(ClinicalTrials.gov)
September 13, 202117/5/2021Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin DeficiencyDrug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administrationFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauInstituto de Salud Carlos IIIRecruiting18 Years65 YearsAll52Phase 4Spain

78. 下垂体前葉機能低下症


臨床試験数 : 492 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04897802
(ClinicalTrials.gov)
September 13, 202117/5/2021Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin DeficiencyDrug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administrationFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauInstituto de Salud Carlos IIIRecruiting18 Years65 YearsAll52Phase 4Spain
2EUCTR2020-004115-27-ES
(EUCTR)
10/05/202101/09/2021Identification and clinical relevance of oxytocin deficient status: GLP1 studyIdentification and clinical relevance of oxytocin deficient status: randomized, crossover, placebo-controlled pathophysiological pilot study: GLP1 study Hypopituitarism;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Trade Name: Byetta
INN or Proposed INN: EXENATIDE
Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant PauNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
52Phase 2Spain

193. プラダー・ウィリ症候群


臨床試験数 : 113 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01444898
(ClinicalTrials.gov)
March 201227/9/2011Effects of Exenatide on Overweight Adolescents With Prader-Willi SyndromeEffects of Exenatide on Obesity and Appetite in Overweight Patients With Prader-Willi SyndromePrader-Willi SyndromeDrug: ExenatideChildren's Hospital Los AngelesNULLCompleted13 Years20 YearsAll10N/AUnited States
2EUCTR2010-023179-25-GB
(EUCTR)
13/09/201127/07/2011Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects of exenatide on appetite and ghrelin in Prader-Willi SyndromeEffects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects of exenatide on appetite and ghrelin in Prader-Willi Syndrome Ghrelin levels in patients with Prader Willi Syndrome and healthy controls and response of ghrelin levels to a single exenatide injection compared with placebo (0.9% sodium chloride) injection.
MedDRA version: 14.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: Byetta
Product Name: Byetta
Product Code: EU/1/06/362/003: 5µg (1 pen)
INN or Proposed INN: exenatide
Aintree University Hospital NHS Foundation TrustUNIVERSITY OF LIVERPOOLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
United Kingdom
3NCT00551343
(ClinicalTrials.gov)
October 200729/10/2007Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi SyndromeContribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome.Prader-Willi SyndromeDrug: ExenatideGarvan Institute of Medical ResearchNULLCompleted18 Years45 YearsAll20N/AAustralia

233. ウォルフラム症候群


臨床試験数 : 11 薬物数 : 17 - (DrugBank : 8) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 41
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01302327
(ClinicalTrials.gov)
March 201122/2/2011GLP Analogs for Diabetes in Wolfram Syndrome PatientsDiabetes Mellitus Associated With Genetic Syndrome;Wolfram SyndromeDrug: ExenatideHadassah Medical OrganizationNULLNot yet recruiting18 YearsN/ABoth10N/ANULL